Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Evaluation of the Human Papillomavirus mRNA Test for the detection of cervical lesions in Japan
1 Department of Molecular Pathology, Tokyo Medical University, Tokyo
2 Kosei Chuo General Hospital, Tokyo
3 Tsujimaru International Patent Office, Kyoto
4 Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo
5 Hitachi City Endowment for Community Healthcare of Obstetrics Gynecology, Ibaraki (Japan)
Eur. J. Gynaecol. Oncol. 2015, 36(2), 186–191; https://doi.org/10.12892/ejgo2604.2015
Published: 10 April 2015
Aims. For the screening of cervical abnormalities, human papillomavirus (HPV) DNA testing is widely used along with Papanicolaou (Pap) testing. Although the sensitivity of the HPV DNA testing is good, its specificity is relatively low. In the present study, the authors evaluated the use of the Gen-Probe APTIMA HPV Assay for the detection of HPV mRNA and compared it with HPV DNA testing. Materials and Methods. Liquid cervical Pap specimens collected from 410 women were assessed using the APTIMA test, the Qiagen Hybrid Capture 2 HPV DNA (HC2) Test, and the AMPLICOR HPV Test. Results. The sensitivity and specificity for the detection of high-risk HPV were 85.6% and 99.2% for the APTIMA test, 94.1% and 98.4% for the HC2 test, and 90.2% and 95.7% for the AMPLICOR test, respectively. As the severity of the cervical lesion progressed, the positive rate of the three tests indicated a similar increase. The clinical sensitivity and specificity for the detection of squamous intraepithelial lesion (SIL) were 91.2% and 84.2% for the APTIMA test, 94.5% and 80.4% for the HC2 test, and 87.9% and 78.2% for the AMPLICOR test, respectively. Conclusion. The APTIMA is sensitive and specific for the detection of high-risk HPV. In the specimens with SIL, the APTIMA test is more specific than the HC2 and the AMPLICOR tests. This indicates that the APTIMA test may improve patient management and reduce the cost of screening.
Squamous intraepithelial lesion